Motif Bio PLC Investor Presentation
February 08 2017 - 9:57AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
08 February 2017
8 February 2017
Motif Bio plc
("Motif" or the "Company")
Investor Presentation
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces it
will be holding a presentation for investors on Tuesday 21 February
2017.
The event will be held at the Black Bar, upstairs at Rocket Bar,
6 Adams Court, Old Broad Street, London, EC2N 1DX from 4.30pm for a
4.45pm start.
A presentation will be given by the Chief Executive Officer,
Graham Lumsden and the newly appointed Chief Financial Officer,
Robert Dickey IV, and will cover an overview of the Company and the
progress with the REVIVE-1 clinical trial of iclaprim compared to
vancomycin in patients with acute bacterial skin and skin structure
infections. This will be followed by an opportunity to network over
drinks and canapés.
To register for the event, please contact
motifbio@walbrookpr.com or call the Walbrook PR team below.
For further information please contact:
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com
PR & IR)
Mike Wort / Lianne Cawthorne
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalised patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP), which
is often caused by MRSA (methicillin resistant Staphylococcus
aureus). We are currently enrolling and dosing patients in two
global Phase 3 clinical trials (Revive 1 and Revive 2) with an
intravenous formulation of iclaprim, for the treatment of ABSSSI.
Data readout for REVIVE-1 is expected in the second quarter of 2017
and REVIVE-2 is on track for data readout in the second half of
2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFESFEITIID
(END) Dow Jones Newswires
February 08, 2017 09:57 ET (14:57 GMT)
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024